Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD3 | O94806 | 5/20 | 0.71 |
| ▸ | MAP4K4 | O95819 | 5/20 | 0.71 |
| ▸ | CSNK1D | P48730 | 5/20 | 0.71 |
| ▸ | MINK1 | Q8N4C8 | 4/20 | 0.71 |
| ▸ | PRKD2 | Q9BZL6 | 4/20 | 0.71 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.71 |
| ▸ | MAPK14 | Q16539 | 15/20 | 0.64 |
| ▸ | GSK3B | P49841 | 2/20 | 0.60 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.60 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.60 |
| ▸ | GSK3A | P49840 | 1/20 | 0.60 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.60 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.60 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.60 |
| ▸ | EGFR | P00533 | 2/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.52 |
| ▸ | MARK3 | P27448 | 1/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.52 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4298093 | 0.86 | MAP4K4 (0.62) | PRKD3MAP4K4CSNK1DMINK1PRKD2 | |
| SCHEMBL4293949 | 0.85 | MAP4K4 (0.71) | PRKD3MAP4K4CSNK1DMINK1PRKD2 | |
| SCHEMBL4300444 | 0.83 | MAP4K4 (1.00) | PRKD3MAP4K4CSNK1DMINK1PRKD2 | |
| SCHEMBL13144064 | 0.83 | MAPK14 (0.66) | PRKD3MAP4K4CSNK1DMINK1PRKD2 | |
| SCHEMBL3085862 | 0.81 | PRKD3 (0.55) | PRKD3MAP4K4CSNK1DMINK1PRKD2 | |
| SCHEMBL13144065 | 0.81 | MAPK14 (0.66) | PRKD3MAP4K4CSNK1DMINK1PRKD2 | |
| SCHEMBL3088356 | 0.80 | PRKD3 (0.62) | PRKD3MAP4K4CSNK1DMINK1PRKD2 | |
| SCHEMBL17767557 | 0.79 | TGFBR1 (0.56) | PRKD3MAP4K4CSNK1DMINK1PRKD2 | |
| SCHEMBL4764009 | 0.78 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL4303052 | 0.78 | MAP4K4 (0.69) | PRKD3MAP4K4CSNK1DMINK1PRKD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790741-B2 | Imidazothiazoles and imidazoxazoles | ABBOTT LABORATORIES (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790741-B2 | Imidazothiazoles and imidazoxazoles | ABBOTT LABORATORIES (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790741-B2 | Imidazothiazoles and imidazoxazoles | ABBOTT LABORATORIES (US) | 2010-09-07 | — | — | US | disclosed |
| US-20080161341-A1 | Novel imidazothiazoles and imidazoxazoles | ABBVIE INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161341-A1 | Novel imidazothiazoles and imidazoxazoles | ABBVIE INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161341-A1 | Novel imidazothiazoles and imidazoxazoles | ABBVIE INC. | 2008-07-03 | — | — | US | disclosed |
| WO-2008063287-A2 | NOVEL IMIDAZOTHIAZOLES AND IMIDAZOXAZOLES | ABBOTT LABORATORIES (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161341-A1 | Novel imidazothiazoles and imidazoxazoles | MAP3K1, MAP3K19, MAP3K5 | PRKD3 376/4885MAP4K4 26/4885CSNK1D 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.